Treatment of bone diseases with bisphosphonates, excluding osteoporosis

Current Opinion in Rheumatology

Volumn 12, Issue 4, 2000, Pages 331-335

  Devogelaer, Jean Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; SALCATONIN; TILUDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE EROSION; BONE METASTASIS; BONE MINERAL; BONE MINERALIZATION; CLINICAL TRIAL; DRUG INDICATION; DRUG POTENCY; FIBROUS DYSPLASIA; FRACTURE; HUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROSTHESIS LOOSENING; RHEUMATOID ARTHRITIS; SARCOMA; SIDE EFFECT;

ABNORMALITIES, DRUG-INDUCED; ADULT; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; CHILD; DIPHOSPHONATES; FEMALE; FIBROUS DYSPLASIA OF BONE; HUMANS; MALE; MULTIPLE MYELOMA; OSTEITIS DEFORMANS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS;

EID: 0033938962     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200007000-00017     Document Type: Article

References (30)

1. 1 Russell RGG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999, Suppl 2:S66-S80. A comprehensive review of the history, structure, mechanisms of action, safety aspects, and prospects of bisphosphonates.
2. 2 Benford HL, Frith JC, Auriola S, et al.: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two-distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131-140.
3. 3 Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst 1 kinase during apoptosis: a link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999, 274:34967-34973.
4. 4 Fisher JE, Rogers MJ, Halasy JM, et al.: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96:133-138.
5. 5 Siris ES: Goals of treatment for Paget's disease of bone. J Bone Miner Res 1999, 14(suppl 2):49-52. A comprehensive discussion of the goals of therapy in Paget disease in the light of the availability of powerful bisphosphonates.
6. 6 Price RI, Gutteridge DH, Stuckey BGA, et al.: Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium. J Bone Miner Res 1993, 8:209-217.
7. 7 Thiebaud D, Biglet JM, Krieg MA, et al.: Dose response with intravenous pamidronate (APD) in postmenopausal osteoporosis: a comparison of 30 mg and 60 mg doses. Bone Miner 1994, 25(suppl 1):S76.
8. 8 Stewart GO, Gutteridge DH, Price RI, et al.: Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. Bone 1999, 24:139-144.
9. 9 Laroche M, Delpech B, Bernard J, et al.: Measurement of bone mineral density by dual X-ray absorptiometry in Paget's disease before and after pamidronate treatment. Calcif Tissue Int 1999, 65:188-191.
10. 10 Lombardi A: Treatment of Paget's disease of bone with alendronate. Bone 1999, 24(suppl):59S-61S.
11. 11 Brown JP, Hosking DJ, Ste-Marie L-G, et al.: Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Calcif Tissue Int 1999, 64:93-99.
12. 12 Perkins AC, Wilson CG, Frier M, et al.: Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharmacol 1999, 186:169-175.
13. 13 Gonzalez DC, Mautalen CA: Short-term therapy with oral olpadronate in active Paget's disease of bone. J Bone Miner Res 1999, 14:2042-2047.
14. 14 Poncelet A: The neurologic complications of Paget's disease. J Bone Miner Res 1999, 14(suppl 2):88-91.
15. 15 Devogelaer JP, Maldague B: Lumbar spinal stenosis in metabolic bone diseases. In Lumbar Spinal Stenosis. Edited by Gunzburg R, Spalski M. Philadelphia: Lippincott Williams & Wilkins, 2000:61-68.
16. 16 Nagant de Deuxchaisnes C, Maldague B, Malghem J, et al.: The action of the main therapeutic regimes on Paget's disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 1980, 23:1215-1234.
17. 17 Devogelaer J-P, Malghem J, Stasse P, Nagant de Deuxchaisnes C: Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. Bone 1997, 20:259-261.
18. 18 Bell NH, Avery S, Johnston CC Jr: Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. J Clin Endocrinol Metab 1970, 31:283-290.
19. 19 Chapurlat RD, Delmas PD, Liens D, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997, 12:1746-1752.
20. 20 Chapurlat R, Meunier PJ: Bisphosphonates et remodelage osseux: efficacité dans la maladie de Paget, la dysplasie fibreuse et l'ostéoporose. Rev Chir Orthop 1998, 84:734-751.
21. 21 Patlas N, Golomb G, Yaffe P, et al.: Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999, 60:68-73.
22. 22 Surrey ES: Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Fertil Steril 1999, 71:420-424.
23. 23 Berenson JR, Lipton A: Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999, 50:237-248. A summary of the recently published data on the use of bisphosphonates in the treatment of malignant bone disease, demonstrating that bisphosphonates play a major role as adjuvant therapy.
24. 24 McCloskey EV, MacLennan IC, Drayson MT, et al.: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998, 100:317-325.
25. 25 Aparicio A, Gardner A, Tu Y, et al.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220-229.
26. 26 Derenne S, Amiot M, Barillé S, et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999, 14:2048-2056.
27. 27 Hortobagyi GN, Theriault RL, Lipton A, et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998, 16:2038-2044.
28. 28 Magnetto S, Boissier S, Delmas PD, Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999, 83:263-269.
29. 29 Dallas SL, Garrett IR, Oyajobi BO, et al.: Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697-1706.
30. 30 Body JJ, Lortholary A, Romieu G, et al.: A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999, 14:1557-1561.